The primary approach to enhance GLUT1 function is through glucagon-like protein 1 agonists (particularly liraglutide), which have already been approved as a second line treatment for diabetes, though whether AD can be considered as a “diabetes type 3” remains controversial [96]. Here, SLC2A1 is linked to Alzheimer disease.